365 related articles for article (PubMed ID: 29664231)
21. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis.
Simonini G; Pignone A; Generini S; Falcini F; Cerinic MM
Toxicology; 2000 Nov; 155(1-3):1-15. PubMed ID: 11154792
[TBL] [Abstract][Full Text] [Related]
22. The Role of Oxidative Stress in the Development of Systemic Sclerosis Related Vasculopathy.
Abdulle AE; Diercks GFH; Feelisch M; Mulder DJ; van Goor H
Front Physiol; 2018; 9():1177. PubMed ID: 30197602
[TBL] [Abstract][Full Text] [Related]
23. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
24. Attenuated nitric oxide bioavailability in systemic sclerosis: Evidence from the novel assessment of passive leg movement.
Clifton HL; Machin DR; Groot HJ; Frech TM; Donato AJ; Richardson RS; Wray DW
Exp Physiol; 2018 Oct; 103(10):1412-1424. PubMed ID: 29790215
[TBL] [Abstract][Full Text] [Related]
25. Oxidative stress elicits platelet/leukocyte inflammatory interactions via HMGB1: a candidate for microvessel injury in sytemic sclerosis.
Maugeri N; Rovere-Querini P; Baldini M; Baldissera E; Sabbadini MG; Bianchi ME; Manfredi AA
Antioxid Redox Signal; 2014 Mar; 20(7):1060-74. PubMed ID: 24070090
[TBL] [Abstract][Full Text] [Related]
26. Phototherapy in systemic sclerosis: Review.
Chaowattanapanit S; Choonhakarn C; Foocharoen C; Julanon N
Photodermatol Photoimmunol Photomed; 2017 Nov; 33(6):296-305. PubMed ID: 28703365
[TBL] [Abstract][Full Text] [Related]
27. [Systemic sclerosis--pathogenesis, clinical manifestations and treatment].
Radić M; Kaliterna DM; Fabijanić D; Radić J
Lijec Vjesn; 2010; 132(5-6):162-8. PubMed ID: 20677623
[TBL] [Abstract][Full Text] [Related]
28. Increasing levels of serum antioxidant status, total antioxidant power, in systemic sclerosis.
Ogawa F; Shimizu K; Muroi E; Hara T; Sato S
Clin Rheumatol; 2011 Jul; 30(7):921-5. PubMed ID: 21327687
[TBL] [Abstract][Full Text] [Related]
29. Macro- and microvascular disease in systemic sclerosis.
Kavian N; Batteux F
Vascul Pharmacol; 2015 Aug; 71():16-23. PubMed ID: 26044180
[TBL] [Abstract][Full Text] [Related]
30. Decreased activation of ataxia telangiectasia mutated (ATM) in monocytes from patients with systemic sclerosis.
Sakata K; Yasuoka H; Yoshimoto K; Takeuchi T
Rheumatology (Oxford); 2020 Dec; 59(12):3961-3970. PubMed ID: 32743653
[TBL] [Abstract][Full Text] [Related]
31. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development.
Lambrecht S; Smith V; De Wilde K; Coudenys J; Decuman S; Deforce D; De Keyser F; Elewaut D
Arthritis Rheumatol; 2014 Feb; 66(2):418-27. PubMed ID: 24504814
[TBL] [Abstract][Full Text] [Related]
32. A Potential Link Between Oxidative Stress and Endothelial-to-Mesenchymal Transition in Systemic Sclerosis.
Thuan DTB; Zayed H; Eid AH; Abou-Saleh H; Nasrallah GK; Mangoni AA; Pintus G
Front Immunol; 2018; 9():1985. PubMed ID: 30283435
[TBL] [Abstract][Full Text] [Related]
33. Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review.
Fioretto BS; Rosa I; Matucci-Cerinic M; Romano E; Manetti M
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835506
[TBL] [Abstract][Full Text] [Related]
34. Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate.
Dooley A; Shi-Wen X; Aden N; Tranah T; Desai N; Denton CP; Abraham DJ; Bruckdorfer R
Rheumatology (Oxford); 2010 Nov; 49(11):2024-36. PubMed ID: 20627968
[TBL] [Abstract][Full Text] [Related]
35. Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis.
Svegliati S; Marrone G; Pezone A; Spadoni T; Grieco A; Moroncini G; Grieco D; Vinciguerra M; Agnese S; Jüngel A; Distler O; Musti AM; Gabrielli A; Avvedimento EV
Sci Signal; 2014 Sep; 7(341):ra84. PubMed ID: 25185156
[TBL] [Abstract][Full Text] [Related]
36. Systemic sclerosis in adults. Part I: Clinical features and pathogenesis.
Jerjen R; Nikpour M; Krieg T; Denton CP; Saracino AM
J Am Acad Dermatol; 2022 Nov; 87(5):937-954. PubMed ID: 35131402
[TBL] [Abstract][Full Text] [Related]
37. [Autoantibodies in systemic sclerosis and their clinical correlation in patients from a Midwestern region of Brazil].
Coelho Horimoto AM; da Costa IP
Rev Bras Reumatol; 2015; 55(3):229-39. PubMed ID: 25559063
[TBL] [Abstract][Full Text] [Related]
38. Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy.
Shima Y
Cells; 2021 May; 10(5):. PubMed ID: 34064515
[TBL] [Abstract][Full Text] [Related]
39. Localization of endothelin-1 and its binding sites in scleroderma skin.
Vancheeswaran R; Azam A; Black C; Dashwood MR
J Rheumatol; 1994 Jul; 21(7):1268-76. PubMed ID: 7525957
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.
Ferreli C; Gasparini G; Parodi A; Cozzani E; Rongioletti F; Atzori L
Clin Rev Allergy Immunol; 2017 Dec; 53(3):306-336. PubMed ID: 28712039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
